Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.48 USD | +0.67% | +6.72% | -4.29% |
Apr. 30 | Guggenheim Starts Precision BioSciences With Buy Rating, $19 Price Target | MT |
Apr. 16 | Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration | MT |
Financials (USD)
Sales 2024 * | 21.17M | Sales 2025 * | 20.72M | Capitalization | 72.48M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -66M | EV / Sales 2024 * | 0.47 x |
Net cash position 2024 * | 62.43M | Net cash position 2025 * | 135M | EV / Sales 2025 * | -3.01 x |
P/E ratio 2024 * |
-1.38
x | P/E ratio 2025 * |
-1.89
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Precision BioSciences, Inc.
1 day | +0.67% | ||
1 week | +6.72% | ||
Current month | +0.67% | ||
1 month | -31.82% | ||
3 months | -8.07% | ||
6 months | -12.45% | ||
Current year | -4.29% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Amoroso
CEO | Chief Executive Officer | 46 | 21-10-14 |
Jeff Smith
FOU | Founder | - | 06-01-25 |
John Kelly
DFI | Director of Finance/CFO | 57 | 20-10-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Buehler
CHM | Chairman | 66 | 19-11-07 |
Geno Germano
BRD | Director/Board Member | 63 | 20-03-09 |
Director/Board Member | 75 | 21-11-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.16% | 2 M€ | -25.75% | ||
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 10.48 | +0.67% | 35,526 |
24-04-30 | 10.41 | +5.79% | 40,049 |
24-04-29 | 9.84 | +4.90% | 24,534 |
24-04-26 | 9.38 | -3.50% | 28,994 |
24-04-25 | 9.72 | -1.02% | 21,921 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
- Stock Market
- Equities
- DTIL Stock